A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: chidamide|DRUG: camrelizumab|DRUG: carboplatin|DRUG: capecitabine
Sponsor: Fudan University